Kymera Therapeutics stock slides nearly 7% after CEO share-sale filing — what KYMR investors watch next
Kymera Therapeutics Inc shares fell nearly 7% on Friday afternoon after a regulatory filing disclosed a year-end sale by Chief Executive Nello Mainolfi. Kymera was down 6.9% at $72.42, after earlier touching $72.18.
